Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 March 2022 | Story André Damons | Photo UFS Photo Archive
Prof Matsabisa
Prof Motlalepula Matsabisa is a professor and Director of Pharmacology at the University of the Free State (UFS)

The Department of Pharmacology at the University of the Free State (UFS) and FARMOVS have teamed up to conduct the first South African Health Products Regulatory Authority (SAHPRA)-approved multicentre controlled clinical trial of a plant-based product, PHELA, on mild to moderate COVID-19 patients.  

According to Prof Motlalepula Matsabisa, professor and Director of Pharmacology at UFS, it is anticipated that the trial will start in early April with each patient being on treatment for 28 days.

“The main purpose of the clinical trial is to confirm that the product can treat COVID-19 and be registered as a medication for this indication. We believe the medication works as an immune modulator to modulate the cytokine storm due to COVID-19 and also restores and normalises the patient’s immune system. We plan to have 250 patients who suffer from mild to moderate COVID-19,” explains Prof Matsabisa. 

This pivotal study, he says, is based on the modification of the World Health Organisation (WHO) Master protocol for clinical trials. The use of FARMOVS, a wholly owned clinical research company of the UFS Bloemfontein campus, for this clinical trial was to implement the collaborative initiatives between UFS and FARMOVS on clinical research, training, and other research projects.

What is PHELA?

Prof Matsabisa, deputy president of the South African Society for Basic and Clinical Pharmacology Society (SASBCP), says the development of PHELA has been under stringent scientific scrutiny for its safety in both preclinical and clinical research. The efficacy of PHELA as both an immune modulator and an anti-SARS-COV-2 has been proven in vitro and in vivo with reproducible results conducted by three independent research institutions and a science council.
The Department of Pharmacology and FARMOVS are collaborating on a number of studies to advance clinical research on African Traditional Medicines (ATM).

On the use of PHELA, Prof Matsabisa explains: “PHELA is a herbal product made of four medicinal plants. Traditionally PHELA has been claimed for use for a historical disease called muyaga, but recently has been scientifically tested and found effective as an immune modulator and benefiting persons with a compromised immune system.
“The PHELA plants are found in most provinces of South Africa and we have cultivated them to control their growth to produce quality raw materials.” 

“The SAHPRA-approved clinical trial will be conducted in the Eastern Cape, Northern Cape and Gauteng. The clinical trial will be conducted by a complement of medical staff and clinicians with vast experience of many active years of clinical trials.
 
“The study, we believe, is a benchmark for all future traditional medicines clinical trial protocols and studies. The studies are expected to start immediately after the product batch manufacturing of the study product, PHELA, is completed and this will be within a month’s time. “A lot of good scientific preclinical safety and efficacy research has gone into the development of the study product for it to reach this stage.

“The efficacy studies have shown convincingly that PHELA is an immune reconstitution product and does have an effect in killing the SARS-COV-2 virus and most of its variants.  PHELA efficacy, therefore, needs to be confirmed through randomised controlled multicentre clinical trials in COVID-19 patients,” Prof Matsabisa says.

Medicinal plants have previously been used to eradicate life-threatening viruses 

Although medicinal plants have been used to combat previous pandemics such as the Spanish flu, avian influenza and others, we still believe rigorous control and efficacy thereof is still to be supported by scientific research and development, says Prof Matsabisa. 

Prof Matsabisa, the current chairperson of the World Health Organisation’s (WHO) Regional Expert Advisory Committee on Traditional Medicines (REACT), adds: “We have better technologies and resources now, which is why we should take the next step in research to promote consumer safety and to offer them effective alternatives. We do the science to aid in building the herbal industry and develop sustained consumer confidence in traditional medicines. 

Africa should lead the way to a healthier future for all
“My vision is for Africa to share our valuable resources with the world by developing, and distributing world-class medicinal solutions. We should develop and strengthen the pharmaceutical local production of well-researched, quality, safe and efficacious African traditional medicines as commercial products. We are more than capable of doing so and now is the time to do it. Numerous discussions have taken place where other African countries will join South Africa in conducting multicentre studies in clinical trials for traditional medicines. 

“We need to develop or create, based on this current collaborative work with partners like FARMOVS, health centres with a strong focus on African medicines, health products and healing, but in a very strong collaborative initiative with other health systems”, concludes Prof Matsabisa.

Prof Matsabisa was recently awarded a Visiting Professorship at the Beijing University of Chinese Medicine (BUCM) in Beijing, China. He was also recommended to Naledi Pandor, Minister of International Relations and Cooperation, to be part of the India, Brazil and South Africa (IBSA) working group in traditional medicine through his participation in the national department of health technical committee on traditional medicines where he has been appointed by the Minister of Health, Dr Joe Phaahla.

News Archive

UFS breakthrough on SRC
2005-06-10

The Council of the University of the Free State (UFS) today unanimously approved the establishment of a Central Student Representative Council (CSRC)  to ensure the democratic participation of students at its three campuses in the governance of the university.

In a major breakthrough and transformation step for student governance, the Central SRC will include representatives of the main campus in Bloemfontein, the Vista campus and the Qwaqwa campus of the UFS.

The establishment of the Central SRC follows the incorporation of the Qwaqwa campus into the UFS in January 2003 and the incorporation of the Vista campus in Bloemfontein into the UFS in January 2004.

According to Dr Ezekiel Moraka, Vice-Rector: Student Affairs, today’s decision of Council is the result of a lengthy, negotiated agreement between the three campuses. Independent experts facilitated part of the process.

With the establishment of a Central SRC, the UFS has adopted a federal student governance model whereby the CSRC is the highest representative student body on matters of common concern for all students.

However, the three campuses of the UFS will retain autonomous SRC structures for each campus with powers and responsibilities for matters affecting the particular campus.

This arrangement will be reviewed after a year to make allowance for the phasing out of students at the Vista campus, as was agreed in the negotiations preceding the incorporation of that campus into the UFS.

The central SRC will have a maximum of 12 members made up of members of the campus SRCs, including the presidents of these three SRCs. In total, the main campus will have 5 representatives, the Qwaqwa campus will have 4 representatives and the Vista campus will have 3 representatives.

From these 12 members a central SRC president will be chosen on a quarterly basis to represent the general student body at Executive Management, Senate and Council.

In another key decision and significant step forward affecting student governance, the Council also approved amendments the constitution of the Student Representative Council (SRC) of the main campus.  These amendments were the results of deliberations of student organizations, the SRC and the Student Parliament of the UFS main campus.

The amendments to the constitution of the main campus SRC determines that nine of the 18 SRC members must be elected by means of proportional representation and nine on the basis of an individual, first-past-the-post election.

This decision comes in the wake of calls by certain student organizations on main campus for proportional representation to be included as a means of electing student representatives.

The following portfolios of the main campus SRC will be contested by individual candidates on the basis of first past the post:

  • president
  • secretary
  • academic affairs
  • legal and constitutional affairs
  • student development
  • arts and culture
  • men’s internal liaison
  • ladies internal liaison
  • media, marketing and liaison

The following nine portfolios will be contested by affiliated organizations on a proportional representation basis.

  • two vice-presidents
  • treasurerdialogue and associations
  • transformation
  • campus affairs and recreation
  • sport
  • international affairs
  • community service

It also is a breakthrough to have all constitutional changes processed and approved at the June meeting of the Council, with all relevant student organizations having been part of the process and accepting the outcome of the process.

According to the chairperson of the UFS Council, Judge Faan Hancke, today’s unanimous decisions on student governance are an indication of how all UFS stakeholders represented in Council are committed to finding win-win solutions in the interest of the university.

“Once again the UFS has reached another milestone in its transformation and has shown the rest of the country that we are pioneers in the field of reaching intelligent solutions to complex situations,” Judge Hancke said.

According to Dr Moraka, the central SRC constitution will come into effect from the start of the second semester this year.

 MEDIA RELEASE

Issued by: Lacea Loader
    Media Representative
    Tel:  (051) 401-2584
    Cell:  083 645 2454
     E-mail:  loaderl.stg@mail.uovs.ac.za

10 June 2005
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept